Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 239-249

  Kambhampati, Siva P ^a,b   Mishra, Manoj K ^a,b   Mastorakos, Panagiotis ^a   Oh, Yumin ^a   Lutty, Gerard A ^a   Kannan, Rangaramanujam M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Wayne State University   (United States)

Author keywords

Anti inflammatory; Anti VEGF; Dendrimer; Human retinal pigment epithelium; Microglial cells; Ocular drug delivery; Triamcinolone acetonide

Indexed keywords

DENDRIMER; POLYAMIDOAMINE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; PAMAM STARBURST; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; DRUG TRAFFIC; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROGLIA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARTICLE SIZE; PIGMENT EPITHELIUM; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED DRUG RELEASE; THIN LAYER CHROMATOGRAPHY; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOUSE; RETINAL PIGMENT EPITHELIUM; SOLUBILITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DENDRIMERS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICROGLIA; RETINAL PIGMENT EPITHELIUM; SOLUBILITY; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943658467     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.02.013     Document Type: Article

References (55)

1. D.F. Kiernan, and W.F. Mieler The use of intraocular corticosteroids Expert Opin. Pharmacother. 10 2009 2511 2525
2. S.P. Ayalasomayajula, P. Ashton, and U.B. Kompella Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-α-induced angiogenesis in chick chorioallantoic membrane (CAM) J. Ocul. Pharmacol. Ther. 25 2009 97 104
3. X. Zhang, N. Wang, A.P. Schachat, S. Bao, and M.C. Gillies Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema Curr. Mol. Med. 14 2014 376 384
4. X. Zhang, S. Bao, D. Lai, R.W. Rapkins, and M.C. Gillies Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas Diabetes 57 2008 1026 1033
5. S.S. Salek, H.A. Leder, N.J. Butler, T.J. Gan, J.P. Dunn, and J.E. Thorne Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis Ocul. Immunol. Inflamm. 21 2013 257 263
6. W. Li, B. He, W. Dai, Q. Zhang, and Y. Liu Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis Int. Ophthalmol. 34 2014 465 476
7. M.E. Becerra, F. Morescalchi, F. Gandolfo, P. Danzi, G. Nascimbeni, B. Arcidiacono, and et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration Curr. Drug Targets 12 2011 149 172
8. P.L. Penfold, J.G. Wong, J. Gyory, and F.A. Billson Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration Clin. Exp. Ophthalmol. 29 2001 188 192
9. Y. Wang, V.M. Wang, and C.C. Chan The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment Eye 25 2011 127 139
10. S. Matsuda, F. Gomi, Y. Oshima, M. Tohyama, and Y. Tano Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress Invest. Ophthalmol. Vis. Sci. 46 2005 1062 1068
11. M.J. Elman, L.P. Aiello, R.W. Beck, N.M. Bressler, S.B. Bressler, A.R. Edwards, and et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064-77.e35
12. Lekha Gopal, and Tarun Sharma Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration Ind. J. Ophthalmol. 55 6 2007 431
13. C.K. Yeung, K.P. Chan, S.W.Y. Chiang, C.P. Pang, and D.S.C. Lam The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone Invest. Ophthalmol. Vis. Sci. 44 2003 5293 5300
14. C. Durairaj, R.S. Kadam, J.W. Chandler, S.L. Hutcherson, and U.B. Kompella Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin Invest. Ophthalmol. Vis. Sci. 51 2010 5804 5816
15. C.A. Holden, P. Tyagi, A. Thakur, R. Kadam, G. Jadhav, U.B. Kompella, and et al. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs Nanomed. Nanotechnol. Biol. Med. 8 2012 776 783
16. H. Chung, J.J. Hwang, J.Y. Koh, J-g Kim, and Y.H. Yoon Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone Invest. Ophthalmol. Vis. Sci. 48 2007 5742 5749
17. R. Narayanan, J.K. Mungcal, M.C. Kenney, G.M. Seigel, and B.D. Kuppermann Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells Invest. Ophthalmol. Vis. Sci. 47 2006 722 728
18. Y.-S. Chang, C.-F. Lin, C.-L. Wu, P.-Y. Kuo, F.-S. Wu, C.-C. Shieh, and et al. Mechanisms underlying benzyl alcohol cytotoxicity (triamcinolone acetonide preservative) in human retinal pigment epithelial cells Invest. Ophthalmol. Vis. Sci. 52 2011 4214 4222
19. M.E. Kleinman, S.J. Westhouse, J. Ambati, P.A. Pearson, and L.S. Halperin Triamcinolone crystal size Ophthalmology 117 1654 2010 e1 e4
20. S.P. Kambhampati, and R.M. Kannan Dendrimer nanoparticles for ocular drug delivery J. Ocul. Pharmacol. Ther. 29 2013 151 165
21. S.P. Chaplot, and I.D. Rupenthal Dendrimers for gene delivery - a potential approach for ocular therapy? J. Pharm. Pharmacol. 66 2014 542 556
22. U.H. Sk, S.P. Kambhampati, M.K. Mishra, W.G. Lesniak, F. Zhang, and R.M. Kannan Enhancing the efficacy of Ara-C through conjugation with PAMAM dendrimer and linear PEG: a comparative study Biomacromolecules 14 2013 801 810
23. M.K. Mishra, C.A. Beaty, W.G. Lesniak, S.P. Kambhampati, F. Zhang, M.A. Wilson, and et al. Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest ACS Nano 8 2014 2134 2147
24. T.F. Vandamme, and L. Brobeck Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide J. Control. Release 102 2005 23 38
25. R. Iezzi, B.R. Guru, I.V. Glybina, M.K. Mishra, A. Kennedy, and R.M. Kannan Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration Biomaterials 33 2012 979 988
26. W.G. Lesniak, M.K. Mishra, A. Jyoti, B. Balakrishnan, F. Zhang, E. Nance, and et al. Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: effect of neuroinflammation Mol. Pharm. 10 2013 4560 4571
27. S. Kannan, H. Dai, R.S. Navath, B. Balakrishnan, A. Jyoti, J. Janisse, and et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model Sci. Transl. Med. 4 2012 130ra46
28. P. Mastorakos, S.P. Kambhampati, M.K. Mishra, T. Wu, E. Song, J. Hanes, and et al. Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells Nanoscale 2014
29. S. Mansoor, B. Kuppermann, and M.C. Kenney Intraocular sustained-release delivery systems for triamcinolone acetonide Pharm. Res. 26 2009 770 784
30. J. Hong, B.-K. Kim, H. Lim, S. Lee, and S.J. Lee Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor Immunopharmacol. Immunotoxicol. 34 2012 912 918
31. T.A. Macky, C. Oelkers, U. Rix, M.L. Heredia, E. Künzel, M. Wimberly, and et al. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate J. Med. Chem. 45 2002 1122 1127
32. F. Valamanesh, M. Berdugo, F. Sennlaub, M. Savoldelli, C. Goumeaux, M. Houssier, and et al. Effects of triamcinolone acetonide on vessels of the posterior segment of the eye Mol. Vis. 15 2009 2634 2648
33. P.L. Penfold, L. Wen, M.C. Madigan, N.J.C. King, and J.M. Provis Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells Invest. Ophthalmol. Vis. Sci. 43 2002 3125 3130
34. C.F. Krieglstein, and D.N. Granger Adhesion molecules and their role in vascular disease Am. J. Hypertens. 14 2001 S44 S54
35. P.L. Penfold, L. Wen, M.C. Madigan, M.C. Gillies, N.J.C. King, and J.M. Provis Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration Clin. Exp. Immunol. 121 2000 458 465
36. Y.-S. Wang, U. Friedrichs, W. Eichler, S. Hoffmann, and P. Wiedemann Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells Graefe's Arch. Clin. Exp. Ophthalmol. 240 2002 42 48
37. A.D. Pereira, M.C.M. Santos, V.M. Costa, G.A. Pianetti, and G.R. Da Silva Development and validation of a high performance liquid chromatographic method for determination of triamcinolone acetonide from polyurethane intraocular implants Int. J. Pharm. Pharm. Sci. 4 4 2012 132 136
38. A. Bosnjakovic, M.K. Mishra, W. Ren, Y.E. Kurtoglu, T. Shi, D. Fan, and et al. Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation Nanomed. Nanotechnol. Biol. Med. 7 2011 284 294
39. J.A. Gruneich, A. Price, J. Zhu, and S.L. Diamond Cationic corticosteroid for nonviral gene delivery Gene Ther. 11 2004 668 674
40. K. Ma, M.-X. Hu, Y. Qi, J.-H. Zou, L.-Y. Qiu, Y. Jin, and et al. PAMAM-triamcinolone acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity Biomaterials 30 2009 6109 6118
41. P. Szurman, R. Kaczmarek, M.S. Spitzer, G.B. Jaissle, P. Decker, S. Grisanti, and et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells Exp. Eye Res. 83 2006 584 592
42. A. Henn, S. Lund, M. Hedtjam, P. Porzgen, and M. Leist The suitability of BV2 cells as alternative model system for primary microglia cultures or animal experiments of brain inflammation Eur. J. Cell Biol. 88 2009 72
43. B. Wang, R.S. Navath, R. Romero, S. Kannan, and R. Kannan Anti-inflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells Int. J. Pharm. 377 2009 159 168
44. I.V. Glybina, A. Kennedy, P. Ashton, G.W. Abrams, and R. Iezzi Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide Invest. Ophthalmol. Vis. Sci. 50 2009 4847 4857
45. C.S. Paulo, R. Pires das Neves, and L.S. Ferreira Nanoparticles for intracellular-targeted drug delivery Nanotechnology 22 2011 494002
46. M.A. Carrillo-de Sauvage, L. Maatouk, I. Arnoux, M. Pasco, A. Sanz Diez, M. Delahaye, and et al. Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation Cell Death Differ. 20 2013 1546 1557
47. K. Zhang, L. Zhang, and R.N. Weinreb Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma Nat. Rev. Drug Discov. 11 2012 541 559
48. W. Ma, L. Zhao, A.M. Fontainhas, R.N. Fariss, and W.T. Wong Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD PLoS One 4 2009 e7945
49. J. Ambati, J.P. Atkinson, and B.D. Gelfand Immunology of age-related macular degeneration Nat. Rev. Immunol. 13 2013 438 451
50. C.A. McCarthy, R.E. Widdop, D. Deliyanti, and J.L. Wilkinson-Berka Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system Clin. Exp. Pharmacol. Physiol. 40 2013 571 579
51. H.G.T. Blaauwgeers, G.M. Holtkamp, H. Rutten, A.N. Witmer, P. Koolwijk, T.A. Partanen, and et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation Am. J. Pathol. 155 1999 421 428
52. E.A. Felinski, and D.A. Antonetti Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy Curr. Eye Res. 30 2005 949 957
53. Q. Ebrahem, A. Minamoto, G. Hoppe, B. Anand-Apte, and J.E. Sears Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors Invest. Ophthalmol. Vis. Sci. 47 2006 4935 4941
54. M. Nauck, G. Karakiulakis, A.P. Perruchoud, E. Papakonstantinou, and M. Roth Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells Eur. J. Pharmacol. 341 1998 309 315
55. W.B. Benson A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion Evidence-Based Ophthalmol. 11 2010 22 23 10.1097/IEB.0b013e3181c70dc3